Bedaquiline – The fi rst ATP synthase inhibitor against multi drug resistant tuberculosis

Mageshwaran Lakshmanan; Alphienes Stanley Xavier

首页> 外文期刊>Journal of Young Pharmacists >Bedaquiline – The fi rst ATP synthase inhibitor against multi drug resistant tuberculosis

【24h】

Bedaquiline – The fi rst ATP synthase inhibitor against multi drug resistant tuberculosis

机译：Bedaquiline –第一种抗多药结核的ATP合酶抑制剂

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Increasing incidence of MDR-TB, long duration of treatment and co-infection with HIV are the significant problems in achieving the eradication of tuberculosis. Bedaquiline is an anti-tuberculosis drug with unique mechanism of action. It selectively inhibits the mycobacterial energy metabolism i.e. ATP synthesis and found to be effective against all states of Mycobacterium tuberculosis like active, dormant, replicating, non-replicating, intracellular and extracellular. Preclinical studies have shown the efficacy of bedaquiline in terms of reduction in bacterial load and treatment duration. Phase II clinical studies have established the safety, tolerability and earlier sputum conversion time in patients with MDR-TB. In 2012 FDA approved bedaquiline for treatment of MDR-TB and XDR-TB.

机译：耐多药结核病的发病率增加，治疗时间长和艾滋病毒的共同感染是实现消灭结核病的重大问题。贝达喹啉是一种具有独特作用机制的抗结核药。它选择性地抑制了分枝杆菌的能量代谢，即ATP的合成，并被发现对结核分枝杆菌的所有状态都有效，如活跃，休眠，复制，非复制，细胞内和细胞外。临床前研究表明，苯达喹啉在减少细菌负荷和治疗持续时间方面具有疗效。 II期临床研究确定了MDR-TB患者的安全性，耐受性和更早的痰转化时间。 2012年，FDA批准了bedaquiline用于治疗MDR-TB和XDR-TB。

著录项

来源
《Journal of Young Pharmacists》 |2013年第4期|共4页
作者
Mageshwaran Lakshmanan; Alphienes Stanley Xavier;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类药学;
关键词

相似文献

外文文献
中文文献
专利

1. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial [J] . Tweed Conor D., Dawson Rodney, Burger Divan A., The lancet. Respiratory medicine. . 2019,第12期

机译：Bedaquiline，Moxifloxacin，伪造和吡嗪酰胺在前8周治疗药物易受或耐药性肺结核患者：多期，开放标签，部分随机化，第2B期试验
2. Understanding the drug exposure–response relationship of bedaquiline to predict efficacy for novel dosing regimens in the treatment of multidrug‐resistant tuberculosis [J] . Léna?g Tanneau, Mats O. Karlsson, Elin M. Svensson British journal of clinical pharmacology . 2020,第5期

机译：理解BEDAQUILINE的药物暴露关系预测新型剂量方案治疗多药抗性结核病的疗效
3. Understanding the drug exposure–response relationship of bedaquiline to predict efficacy for novel dosing regimens in the treatment of multidrug‐resistant tuberculosis [J] . British Journal of Clinical Pharmacology . 2020,第5期

机译：理解BEDAQUILINE的药物暴露关系预测新型剂量方案治疗多药抗性结核病的疗效
4. Multivariate adaptive regression spline (MARS) methods with application to multi drug-resistant tuberculosis (MDR-TB) prevalence [C] . Septia Devi Prihastuti Yasmirullah, Bambang Widjanarko Otok, Jerry Dwi Trijoyo Purnomo, International Conference on Mathematics, Computational Sciences and Statistics . 2020

机译：多变量自适应回归花键（MARS）方法，适用于多种耐药结核（MDR-TB）患病率
5. Drug Resistance in Mycobacterium tuberculosis: An Investigation of Drug Transporter P-Glycoprotein and an Evaluation of Improved Diagnosis of Drug Resistant Tuberculosis in Cameroonian Pulmonary Tuberculosis Patients [D] . Abanda, Ngu Njei 2017

机译：结核分枝杆菌的耐药性：转运蛋白P-糖蛋白的调查和喀麦隆肺结核患者耐药性结核病改善诊断的评估
6. Bedaquiline – The first ATP synthase inhibitor against multi drug resistant tuberculosis [O] . Mageshwaran Lakshmanan, Alphienes Stanley Xavier 2013

机译：Bedaquiline –第一种抗多药耐药结核的ATP合酶抑制剂
7. Bedaquiline, an FDA-approved drug, inhibits mitochondrial ATP production and metastasis in vivo, by targeting the gamma subunit (ATP5F1C) of the ATP synthase [O] . Marco Fiorillo, Cristian Scatena, Antonio Giuseppe Naccarato, 2021

机译：通过靶向ATP合酶（ATP5F1C）的ATP合酶的γ亚基（ATP5F1C），Bedaquiline抑制了体内的线粒体ATP生产和转移。

Bedaquiline – The fi rst ATP synthase inhibitor against multi drug resistant tuberculosis

摘要

著录项

相似文献

相关主题

期刊订阅